Samuel Marcrom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samuel Marcrom has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Richard A. Popple
University of Alabama Birmingham Birmingham Alabama USA
4 shared publications Andrew M. McDonald
University of Alabama at Birmingham
3 shared publications- Andrew Michael McDonald
University of Alabama at Birmingham, Birmingham, AL 35294, USA
3 shared publications - Dennis N. Stanley
Department of Radiation Oncology The University of Alabama at Birmingham Birmingham Alabama USA
3 shared publications - John B. Fiveash
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL
3 shared publications Richard A. Popple
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, USA
3 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 27 (2) , e70517
In‐Silico Trial of Same‐Day Simulation‐Free Spatially Fractionated Adaptive Radiotherapy (SF 2 ‐ART)
Purpose: Here we present an in‐silico trial of the feasibility and deliverability of a same‐day, simulation‐free workflow for spatially fractionated adaptive radiotherapy (SF 2 ‐ART) using the Varian Ethos platform. Methods and Materials: Ten patients (five thoracic and five extremity), previously treated with spatially fractionated radiotherapy (SFRT), were selected for this in silico trial. A two‐phase regimen was simulated: Phase 1 delivered 12 Gy SBRT to a uniform, predefined high‐dose lattice and 4 Gy to the gross tumor volume (GTV); Phase 2 consisted of 4 additional fractions of 4 Gy to the GTV. The planning workflow was performed entirely in silico, without the need for CT simulation. High‐dose sphere matrices were generated with a custom script and aligned to physician‐defined GTVs. Adaptive plans were created based on CBCT anatomy and evaluated for dosimetric quality, deliverability, and workflow timing. Comparisons were made to the original clinically delivered plans. Mobius3D was used for secondary dose verification. Results: All 10 cases were successfully replanned using the SF 2 ‐ART workflow without simulation‐based imaging. The entire planning and treatment process, including consultation, contouring, adaptive plan generation, and QA, was performed within a single session. Dosimetric comparisons showed minimal differences between simulation‐free adaptive and clinically delivered plans, with target coverage and normal tissue constraints maintained across all cases. Median total estimated workflow time was 166.4 min. Conclusions: This in‐silico study demonstrates the feasibility of delivering spatially fractionated SBRT without simulation CT using a same‐day adaptive workflow. The SF 2 ‐ART approach may enable rapid, high‐quality treatment for patients with urgent or symptomatic presentations and supports future prospective clinical implementation.
- 16 February 2026
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 27 (2) , e70517
Open AccessIn‐Silico Trial of Same‐Day Simulation‐Free Spatially Fractionated Adaptive Radiotherapy (SF 2 ‐ART)
Purpose: Here we present an in‐silico trial of the feasibility and deliverability of a same‐day, simulation‐free workflow for spatially fractionated adaptive radiotherapy (SF 2 ‐ART) using the Varian Ethos platform. Methods and Materials: Ten patients (five thoracic and five extremity), previously treated with spatially fractionated radiotherapy (SFRT), were selected for this in silico trial. A two‐phase regimen was simulated: Phase 1 delivered 12 Gy SBRT to a uniform, predefined high‐dose lattice and 4 Gy to the gross tumor volume (GTV); Phase 2 consisted of 4 additional fractions of 4 Gy to the GTV. The planning workflow was performed entirely in silico, without the need for CT simulation. High‐dose sphere matrices were generated with a custom script and aligned to physician‐defined GTVs. Adaptive plans were created based on CBCT anatomy and evaluated for dosimetric quality, deliverability, and workflow timing. Comparisons were made to the original clinically delivered plans. Mobius3D was used for secondary dose verification. Results: All 10 cases were successfully replanned using the SF 2 ‐ART workflow without simulation‐based imaging. The entire planning and treatment process, including consultation, contouring, adaptive plan generation, and QA, was performed within a single session. Dosimetric comparisons showed minimal differences between simulation‐free adaptive and clinically delivered plans, with target coverage and normal tissue constraints maintained across all cases. Median total estimated workflow time was 166.4 min. Conclusions: This in‐silico study demonstrates the feasibility of delivering spatially fractionated SBRT without simulation CT using a same‐day adaptive workflow. The SF 2 ‐ART approach may enable rapid, high‐quality treatment for patients with urgent or symptomatic presentations and supports future prospective clinical implementation.
- Open Access
A roadmap for implementation of kV-CBCT online adaptive radiation therapy and initial first year experiences
Purpose: Online Adaptive Radiation Therapy(oART) follows a different treatment paradigm than conventional radiotherapy and, because of this, the resources, implementation, and workflows needed are unique. The purpose of this report is to outline our institution’s experience establishing, organizing, and implementing an oART program using the Ethos therapy system. Methods: We include resources used; operational models utilized, program creation timelines, and our institutional experiences with implementation and operation of an oART program. Additionally, we provide a detailed summary of our first year’s clinical experience where we delivered over 1000 daily adaptive fractions. For all treatments, the different stages of online adaption, primary patient set-up, initial kV-CBCT acquisition, contouring review and edit of influencer structures, target review and edits, plan evaluation and selection, Mobius3D 2 nd check and adaptive QA, 2 nd kV-CBCT for positional verification, treatment delivery, and patient leaving the room, were analyzed. Results: We retrospectively analyzed data from ninety-seven patients treated from August 2021-August 2022. 1677 individual fractions were treated and analyzed, 632(38%) were non-adaptive and 1045(62%) were adaptive. 74 of the 97 patients (76%) were treated with standard fractionation and 23 (24%) received stereotactic treatments. For the adaptive treatments, the generated adaptive plan was selected in 92% of treatments. On average(±std), adaptive sessions took 34.52±11.42 minutes from start to finish. The entire adaptive process (from start of contour generation to verification CBCT), performed by the physicist (and physician on select days), was 19.84±8.21 minutes. Conclusion: We present our institution’s experience commissioning an oART program using the Ethos therapy system. It took us 12 months from project inception to treatment of our first patient and 12 months to treat 1000 adaptive fractions. Retrospective analysis of delivered fractions showed that average overall treatment time was approximately 35 minutes and average time for the adaptive component of treatment was approximately 20 minutes.
Open AccessA roadmap for implementation of kV-CBCT online adaptive radiation therapy and initial first year experiences
Purpose: Online Adaptive Radiation Therapy(oART) follows a different treatment paradigm than conventional radiotherapy and, because of this, the resources, implementation, and workflows needed are unique. The purpose of this report is to outline our institution’s experience establishing, organizing, and implementing an oART program using the Ethos therapy system. Methods: We include resources used; operational models utilized, program creation timelines, and our institutional experiences with implementation and operation of an oART program. Additionally, we provide a detailed summary of our first year’s clinical experience where we delivered over 1000 daily adaptive fractions. For all treatments, the different stages of online adaption, primary patient set-up, initial kV-CBCT acquisition, contouring review and edit of influencer structures, target review and edits, plan evaluation and selection, Mobius3D 2 nd check and adaptive QA, 2 nd kV-CBCT for positional verification, treatment delivery, and patient leaving the room, were analyzed. Results: We retrospectively analyzed data from ninety-seven patients treated from August 2021-August 2022. 1677 individual fractions were treated and analyzed, 632(38%) were non-adaptive and 1045(62%) were adaptive. 74 of the 97 patients (76%) were treated with standard fractionation and 23 (24%) received stereotactic treatments. For the adaptive treatments, the generated adaptive plan was selected in 92% of treatments. On average(±std), adaptive sessions took 34.52±11.42 minutes from start to finish. The entire adaptive process (from start of contour generation to verification CBCT), performed by the physicist (and physician on select days), was 19.84±8.21 minutes. Conclusion: We present our institution’s experience commissioning an oART program using the Ethos therapy system. It took us 12 months from project inception to treatment of our first patient and 12 months to treat 1000 adaptive fractions. Retrospective analysis of delivered fractions showed that average overall treatment time was approximately 35 minutes and average time for the adaptive component of treatment was approximately 20 minutes.
- Open Access
- 24 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e26303
Dose Optimization for Single-Channel Vaginal Cylinder High-Dose-Rate Brachytherapy: A Double Prescription Method for Patients With Endometrial Adenocarcinoma
This study aimed to explore the relationship between applicator surface dose and 5 mm-depth dose and to optimize both locations simultaneously for three most used cylinder sizes (2.5, 3.0, and 3.5 cm in diameter) in treating patients with endometrial adenocarcinoma. A total of 216 plans were created for each dose level and applicator size. For each dose level, four plans were created with single or double prescription doses. For plans with double prescription doses, the dose constraints were applied to all those points on the surface and 5 mm depth and optimize the two sites simultaneously. A dose table between surface and 5 mm depth and its fifth order polynomial mapping functions were established for each applicator size, so any prescribed dose at one site can find the prescription dose on the other site in optimization on both locations. For plans with a 5 mm-depth prescription, the maximum dose on the surface can be reduced from 145% to 133% if the surface prescription dose is also used; for plans with surface dose prescription, the minimum dose and mean dose can be improved by 2% if 5 mm-depth dose prescription is also used in optimization. Dose table and their mapping functions between surface prescription dose and their corresponding 5 mm-depth doses were created. A new optimization method that uses two prescription doses on both surface and 5 mm-depth sites was proposed to reduce the hot dose on the surface and improve the cold dose at 5 mm depth.
- 24 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e26303
Open AccessDose Optimization for Single-Channel Vaginal Cylinder High-Dose-Rate Brachytherapy: A Double Prescription Method for Patients With Endometrial Adenocarcinoma
This study aimed to explore the relationship between applicator surface dose and 5 mm-depth dose and to optimize both locations simultaneously for three most used cylinder sizes (2.5, 3.0, and 3.5 cm in diameter) in treating patients with endometrial adenocarcinoma. A total of 216 plans were created for each dose level and applicator size. For each dose level, four plans were created with single or double prescription doses. For plans with double prescription doses, the dose constraints were applied to all those points on the surface and 5 mm depth and optimize the two sites simultaneously. A dose table between surface and 5 mm depth and its fifth order polynomial mapping functions were established for each applicator size, so any prescribed dose at one site can find the prescription dose on the other site in optimization on both locations. For plans with a 5 mm-depth prescription, the maximum dose on the surface can be reduced from 145% to 133% if the surface prescription dose is also used; for plans with surface dose prescription, the minimum dose and mean dose can be improved by 2% if 5 mm-depth dose prescription is also used in optimization. Dose table and their mapping functions between surface prescription dose and their corresponding 5 mm-depth doses were created. A new optimization method that uses two prescription doses on both surface and 5 mm-depth sites was proposed to reduce the hot dose on the surface and improve the cold dose at 5 mm depth.
- Open Access
- 14 February 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-9
Hypofractionated radiation leads to more rapid bleeding cessation in women with vaginal bleeding secondary to gynecologic malignancy
Background: Vaginal bleeding (VB) is common in women with gynecologic (GYN) malignancies. Radiation therapy (RT) is used for the definitive treatment of GYN cancers and palliation of bleeding. The historical dogma is that high dose-per-fraction radiation leads to more rapid bleeding cessation, yet there is scant data supporting this claim. We sought to examine the effect of RT fraction size on VB via retrospective analysis of patients receiving hypofractionated radiation (HFRT) compared to conventionally fractionated radiation (CFRT) for control of bleeding secondary to GYN malignancies. Methods: We identified patients receiving external beam RT for continuous VB from GYN malignancy treated in our department from 2012 to 2020. RT was classified as HFRT (> 2.0 Gy/fx) or CFRT (1.8–2.0 Gy/fx). Demographic information, disease characteristics, and treatment details were collected. The primary endpoint was days from RT initiation until bleeding resolution. Characteristics between groups were compared via Fisher’s exact test. Time to bleeding cessation was assessed via Kaplan–Meier and log-rank test. Univariable and multivariable Cox-proportional hazards were used to identify factors associated with bleeding cessation. Results: We identified 43 patients meeting inclusion criteria with 26 and 17 patients receiving CFRT and HFRT, respectively. Comparison of baseline characteristics revealed patients receiving HFRT were older (p = 0.001), more likely to be post-menopausal (p = 0.002), and less likely to receive concurrent chemotherapy (p = 0.004). Time to bleeding cessation was significantly shorter for patients receiving HFRT (log-rank p < 0.001) with median time to bleeding cessation of 5 days (HFRT) versus 16 days (CFRT). Stratification by dose-per-fraction revealed a dose–response effect with more rapid bleeding cessation with increased dose-per-fraction. While HFRT, age, recurrent disease, prior pelvic RT, and prior systemic therapy were associated with time to bleeding cessation on univariable analysis, HFRT was the only factor significantly associated with time to bleeding cessation in the final multivariable model (HR 3.26, p = 0.008). Conclusions: Patients with continuous VB from GYN tumors receiving HFRT experienced more rapid bleeding cessation than those receiving CFRT. For patients with severe VB, initiation of HFRT to control malignancy related bleeding quickly may be warranted.
- 14 February 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-9
Open AccessHypofractionated radiation leads to more rapid bleeding cessation in women with vaginal bleeding secondary to gynecologic malignancy
Background: Vaginal bleeding (VB) is common in women with gynecologic (GYN) malignancies. Radiation therapy (RT) is used for the definitive treatment of GYN cancers and palliation of bleeding. The historical dogma is that high dose-per-fraction radiation leads to more rapid bleeding cessation, yet there is scant data supporting this claim. We sought to examine the effect of RT fraction size on VB via retrospective analysis of patients receiving hypofractionated radiation (HFRT) compared to conventionally fractionated radiation (CFRT) for control of bleeding secondary to GYN malignancies. Methods: We identified patients receiving external beam RT for continuous VB from GYN malignancy treated in our department from 2012 to 2020. RT was classified as HFRT (> 2.0 Gy/fx) or CFRT (1.8–2.0 Gy/fx). Demographic information, disease characteristics, and treatment details were collected. The primary endpoint was days from RT initiation until bleeding resolution. Characteristics between groups were compared via Fisher’s exact test. Time to bleeding cessation was assessed via Kaplan–Meier and log-rank test. Univariable and multivariable Cox-proportional hazards were used to identify factors associated with bleeding cessation. Results: We identified 43 patients meeting inclusion criteria with 26 and 17 patients receiving CFRT and HFRT, respectively. Comparison of baseline characteristics revealed patients receiving HFRT were older (p = 0.001), more likely to be post-menopausal (p = 0.002), and less likely to receive concurrent chemotherapy (p = 0.004). Time to bleeding cessation was significantly shorter for patients receiving HFRT (log-rank p < 0.001) with median time to bleeding cessation of 5 days (HFRT) versus 16 days (CFRT). Stratification by dose-per-fraction revealed a dose–response effect with more rapid bleeding cessation with increased dose-per-fraction. While HFRT, age, recurrent disease, prior pelvic RT, and prior systemic therapy were associated with time to bleeding cessation on univariable analysis, HFRT was the only factor significantly associated with time to bleeding cessation in the final multivariable model (HR 3.26, p = 0.008). Conclusions: Patients with continuous VB from GYN tumors receiving HFRT experienced more rapid bleeding cessation than those receiving CFRT. For patients with severe VB, initiation of HFRT to control malignancy related bleeding quickly may be warranted.
- Open Access
- 14 June 2020
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8618
Reduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancers
Our study reports the clinical outcomes of patients treated with 5-mm isotropic margin, fiducial-guided stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC). We also sought to assess the effect of histological subtype on local control. We retrospectively reviewed the charts of all patients treated with SBRT for NSCLC between 2007 and 2017 at our institution. All patients who had implanted fiducial markers, planning target volume (PTV) margins of 5 mm or less, early stage disease (T1-T2, N0), and at least one follow-up CT were included in this analysis. Estimates of local control were generated using the Kaplan-Meier method, and differences between survival curves were assessed using the log-rank test. A total of 152 patients met the inclusion criteria for this analysis, with a median follow-up of 27.9 months. Patients received 54 Gy in three fractions for peripheral tumors and 48-52.5 Gy in four to five fractions for central tumors. NSCLC histology was adenocarcinoma in 69 (45.4%) cases, squamous cell carcinoma in 65 (42.8%) cases, and other or non-subtyped in 18 (11.8%) cases. Across the entire cohort, the two-year estimate of local control was 95.1%. When histology was considered, the two-year estimate of local control among patients with adenocarcinoma was 95.6% as compared with 85.0% for patients with other subtypes (p=0.044). Fiducial-guided, isotropic 5-mm PTV margin for thoracic SBRT did not compromise local control compared with historical standards. In this series, patients with adenocarcinoma experienced improved local control compared with squamous cell carcinoma.
- 14 June 2020
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8618
Open AccessReduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancers
Our study reports the clinical outcomes of patients treated with 5-mm isotropic margin, fiducial-guided stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC). We also sought to assess the effect of histological subtype on local control. We retrospectively reviewed the charts of all patients treated with SBRT for NSCLC between 2007 and 2017 at our institution. All patients who had implanted fiducial markers, planning target volume (PTV) margins of 5 mm or less, early stage disease (T1-T2, N0), and at least one follow-up CT were included in this analysis. Estimates of local control were generated using the Kaplan-Meier method, and differences between survival curves were assessed using the log-rank test. A total of 152 patients met the inclusion criteria for this analysis, with a median follow-up of 27.9 months. Patients received 54 Gy in three fractions for peripheral tumors and 48-52.5 Gy in four to five fractions for central tumors. NSCLC histology was adenocarcinoma in 69 (45.4%) cases, squamous cell carcinoma in 65 (42.8%) cases, and other or non-subtyped in 18 (11.8%) cases. Across the entire cohort, the two-year estimate of local control was 95.1%. When histology was considered, the two-year estimate of local control among patients with adenocarcinoma was 95.6% as compared with 85.0% for patients with other subtypes (p=0.044). Fiducial-guided, isotropic 5-mm PTV margin for thoracic SBRT did not compromise local control compared with historical standards. In this series, patients with adenocarcinoma experienced improved local control compared with squamous cell carcinoma.
- Open Access
- 1 January 2020
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 5 (1) , 34-42
Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease
- 1 January 2020
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 5 (1) , 34-42
Open AccessFocal Management of Large Brain Metastases and Risk of Leptomeningeal Disease
- 1 September 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 102 (1) , 16-17
A Fellow's Fate: Employment Outcomes of Radiation Oncology Fellowship Graduates
- 1 September 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 102 (1) , 16-17
A Fellow's Fate: Employment Outcomes of Radiation Oncology Fellowship Graduates
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 2070
Timing, presentation, and patterns of failure of leptomeningeal disease after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis.
2070 Background: Postoperative (post-op) radiosurgery (SRS) has been proposed as a standard of care based on 2 phase III trials, but has been associated with up to 30% risk of leptomeningeal disease (LMD). The specifics of timing, presentation, and patterns of LMD failure have not been well described. Methods: The records of patients (pts) with brain metastases (BM), of which 1 was resected and treated with post-op or pre-op SRS, and who subsequently developed LMD were combined from 7 tertiary care centers. Pts with classically radiosensitive tumors or prior or planned whole brain radiotherapy were excluded. LMD pattern was categorized as either nodular or linear (“sugarcoating”). Results: The study cohort consisted of 147 pts. The most common primary sites were lung (40%), breast (24%), and melanoma (16%), and most pts received post-op SRS (94%). Pts with breast primary were enriched for HER-2 positivity (60%). The majority of resected BM (82%) extended to within 5 mm of the pial surface. Median time from initial SRS to 1st LMD was 5.6 months (interquartile range [IQR] 3.2 – 11). The majority of LMD events were nodular (60%), of which 64% were within 5 cm of the surgical corridor. The median number of nodules was 2 (IQR 1 – 4), with a median distance of 2.5 cm from the surgical corridor (IQR 1.1 – 5.2). Most pts (60%) were symptomatic at time of LMD diagnosis, of which the most common symptoms were headache (58%), cranial nerve deficit (28%), and dizziness/balance issues (24%). Of the pts who received LMD treatment and had follow-up imaging (n = 101), 50% experienced 2nd LMD at a median of 5.5 months after 1st LMD (IQR 2.8 – 9.4). Of these, 68% were symptomatic at the time of 2nd LMD diagnosis, 58% had nodular LMD with a median of 1 nodule (IQR 1-3), and 70% underwent salvage therapy. Conclusions: LMD failure is an increasingly recognized event after surgery and SRS for BM. Pts who experience LMD are enriched in HER-2 positive disease and superficial location of the resected BM. Nodular LMD is the predominant pattern of LMD failure in this pt population, with most LMD events being symptomatic. 2nd LMD is common after initial salvage therapy and also has a predominantly nodular pattern.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 2070
Timing, presentation, and patterns of failure of leptomeningeal disease after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis.
2070 Background: Postoperative (post-op) radiosurgery (SRS) has been proposed as a standard of care based on 2 phase III trials, but has been associated with up to 30% risk of leptomeningeal disease (LMD). The specifics of timing, presentation, and patterns of LMD failure have not been well described. Methods: The records of patients (pts) with brain metastases (BM), of which 1 was resected and treated with post-op or pre-op SRS, and who subsequently developed LMD were combined from 7 tertiary care centers. Pts with classically radiosensitive tumors or prior or planned whole brain radiotherapy were excluded. LMD pattern was categorized as either nodular or linear (“sugarcoating”). Results: The study cohort consisted of 147 pts. The most common primary sites were lung (40%), breast (24%), and melanoma (16%), and most pts received post-op SRS (94%). Pts with breast primary were enriched for HER-2 positivity (60%). The majority of resected BM (82%) extended to within 5 mm of the pial surface. Median time from initial SRS to 1st LMD was 5.6 months (interquartile range [IQR] 3.2 – 11). The majority of LMD events were nodular (60%), of which 64% were within 5 cm of the surgical corridor. The median number of nodules was 2 (IQR 1 – 4), with a median distance of 2.5 cm from the surgical corridor (IQR 1.1 – 5.2). Most pts (60%) were symptomatic at time of LMD diagnosis, of which the most common symptoms were headache (58%), cranial nerve deficit (28%), and dizziness/balance issues (24%). Of the pts who received LMD treatment and had follow-up imaging (n = 101), 50% experienced 2nd LMD at a median of 5.5 months after 1st LMD (IQR 2.8 – 9.4). Of these, 68% were symptomatic at the time of 2nd LMD diagnosis, 58% had nodular LMD with a median of 1 nodule (IQR 1-3), and 70% underwent salvage therapy. Conclusions: LMD failure is an increasingly recognized event after surgery and SRS for BM. Pts who experience LMD are enriched in HER-2 positive disease and superficial location of the resected BM. Nodular LMD is the predominant pattern of LMD failure in this pt population, with most LMD events being symptomatic. 2nd LMD is common after initial salvage therapy and also has a predominantly nodular pattern.
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S172-S173
Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S172-S173
Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease
- Open Access
- 1 October 2017
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 2 (4) , 564-571
Fractionated stereotactic radiation therapy for intact brain metastases
- 1 October 2017
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 2 (4) , 564-571
Open AccessFractionated stereotactic radiation therapy for intact brain metastases